Innospec Stock Price, News & Analysis (NASDAQ:IOSP)

Innospec trades on the NASDAQ under the ticker symbol "IOSP."

Innospec declared a Semi-Annual dividend on Tuesday, May 7th. Stockholders of record on Tuesday, May 21st will be given a dividend of $0.50 per share on Thursday, May 30th. This represents a dividend yield of 1.18%. The ex-dividend date is Monday, May 20th. View Innospec's Dividend History.

Innospec Inc. (NASDAQ:IOSP) announced its earnings results on Tuesday, August, 6th. The specialty chemicals company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.02. The specialty chemicals company earned $362.40 million during the quarter, compared to analyst estimates of $371.20 million. Innospec had a return on equity of 15.11% and a net margin of 6.10%. The firm's quarterly revenue was up 1.2% on a year-over-year basis. During the same period last year, the firm earned $0.80 EPS. View Innospec's Earnings History.

Innospec is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Innospec.

Innospec will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

2 brokerages have issued 1 year target prices for Innospec's shares. Their forecasts range from $83.00 to $95.00. On average, they expect Innospec's share price to reach $89.00 in the next year. This suggests that the stock has a possible downside of 2.5%. View Analyst Price Targets for Innospec.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innospec in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innospec.

Press coverage about IOSP stock has trended somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innospec earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave media headlines about the specialty chemicals company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Innospec.

Innospec saw a decrease in short interest in September. As of September 30th, there was short interest totalling 342,200 shares, a decrease of 10.1% from the August 30th total of 380,700 shares. Based on an average daily volume of 115,700 shares, the short-interest ratio is currently 3.0 days. Currently, 1.4% of the shares of the company are short sold. View Innospec's Current Options Chain.

Some companies that are related to Innospec include Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co (GRA), KURARAY CO LTD/ADR (KURRY), Ingevity (NGVT), Univar (UNVR), Balchem (BCPC), Olin (OLN), Chemours (CC), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM), Innophos (IPHS) and Hawkins (HWKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innospec investors own include Intellia Therapeutics (NTLA), NVIDIA (NVDA), Applied Materials (AMAT), B&G Foods (BGS), Colgate-Palmolive (CL), Emerson Electric (EMR), UnitedHealth Group (UNH), XPO Logistics (XPO), Zayo Group (ZAYO) and Adobe (ADBE).

Innospec's stock is owned by a number of of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.08%) and Diversified Trust Co (0.01%). Company insiders that own Innospec stock include Brian Watt, Catherine Hessner, David Earl Williams, Hugh Aldous, Ian Cleminson, Ian Malcolm Mcrobbie, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View Institutional Ownership Trends for Innospec.

IOSP stock was sold by a variety of institutional investors in the last quarter, including Diversified Trust Co. Company insiders that have sold Innospec company stock in the last year include Brian Watt, Catherine Hessner, Ian Cleminson, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View Insider Buying and Selling for Innospec.

IOSP stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. View Insider Buying and Selling for Innospec.

Shares of IOSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IOSP stock can currently be purchased for approximately $91.30.

Innospec has a market capitalization of $2.24 billion and generates $1.48 billion in revenue each year. The specialty chemicals company earns $85 million in net income (profit) each year or $4.83 on an earnings per share basis. Innospec employs 2,000 workers across the globe.View Additional Information About Innospec.

The official website for Innospec is http://www.innospecinc.com/.

Innospec's mailing address is 8310 SOUTH VALLEY HIGHWAY SUITE 350, ENGLEWOOD CO, 80112. The specialty chemicals company can be reached via phone at 303-792-5554 or via email at [email protected]